Form 13G Akari Therapeutics For: 8 June
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Akari Therapeutics PLC (AKTX)
Akari Therapeutics PLC stock price live, this page displays NASDAQ AKTX stock exchange data. View the AKTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Akari Therapeutics PLC real time stock price chart below.
What Is the Akari Therapeutics PLC Stock Price Today?
The Akari Therapeutics PLC stock price today is 13.4250.
What Is the Stock Symbol for Akari Therapeutics PLC?
The stock symbol for Akari Therapeutics PLC is "AKTX."
What Stock Exchange Does Akari Therapeutics PLC Trade On?
Akari Therapeutics PLC is listed and trades on the NASDAQ stock exchange.
Is Akari Therapeutics PLC a Good Stock to Buy?
Determining whether Akari Therapeutics PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AKTX quote. (ISIN: US00972G4055)
What Is the Akari Therapeutics PLC Stock Price Today?
The Akari Therapeutics PLC stock price today is 13.4250.
What Is the Stock Symbol for Akari Therapeutics PLC?
The stock symbol for Akari Therapeutics PLC is "AKTX."
What Stock Exchange Does Akari Therapeutics PLC Trade On?
Akari Therapeutics PLC is listed and trades on the NASDAQ stock exchange.
Is Akari Therapeutics PLC a Good Stock to Buy?
Determining whether Akari Therapeutics PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AKTX quote. (ISIN: US00972G4055)
NASDAQ
Currency in USD
13.4250
+0.0250(+0.19%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.0000
14.0450
52 wk Range
3.0150
49.9440
AKTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.000014.0450
52 wk Range
3.015049.9440
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AKTX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
26.7800
Upside
+99.48%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 26.7800
(+99.48% Upside)
Earnings
Latest Release
May 14, 2026
EPS / Forecast
-1.33 / -0.04
Revenue / Forecast
-- / --
Compare AKTX to Peers and Sector
Metrics to compare | AKTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAKTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.5x | −2.9x | −0.5x | |
PEG Ratio | −0.02 | 0.07 | 0.00 | |
Price/Book | 1.1x | 3.0x | 2.6x | |
Price / LTM Sales | - | 103.5x | 3.0x | |
Upside (Analyst Target) | 99.9% | 179.0% | 58.6% | |
Fair Value Upside | Unlock | −4.6% | 10.2% | Unlock |
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
People Also Watch
FAQ
What Is the Akari Therapeutics (AKTX) Stock Price Today?
The Akari Therapeutics stock price today is 13.4250 USD.
What Stock Exchange Does Akari Therapeutics Trade On?
Akari Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Akari Therapeutics?
The stock symbol for Akari Therapeutics is "AKTX."
What Is the Akari Therapeutics Market Cap?
As of today, Akari Therapeutics market cap is 15.3400M USD.
What Is Akari Therapeutics's Earnings Per Share (TTM)?
The Akari Therapeutics EPS (TTM) is -26.9141.
When Is the Next Akari Therapeutics Earnings Date?
Akari Therapeutics will release its next earnings report on Aug 18, 2026.
From a Technical Analysis Perspective, Is AKTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Akari Therapeutics Stock Split?
Akari Therapeutics has split 3 times.
How Many Employees Does Akari Therapeutics Have?
Akari Therapeutics has 6 employees.
What is the current trading status of Akari Therapeutics (AKTX)?
As of Jun 15, 2026, Akari Therapeutics (AKTX) is trading at a price of 13.4250 USD, with a previous close of 13.4000 USD. The stock has fluctuated within a day range of 13.0000 USD to 14.0450 USD, while its 52-week range spans from 3.0150 USD to 49.9440 USD.
What Is Akari Therapeutics (AKTX) Price Target According to Analysts?
The average 12-month price target for Akari Therapeutics is 26.7800 USD, with a high estimate of 26.78 USD and a low estimate of 26.78 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +99.48% Upside potential.
What Is the AKTX Premarket Price?
AKTX's last pre-market stock price is 13.5000 USD. The pre-market share volume is 360.0000, and the stock has decreased by 0.1000, or 0.7500%.
What Is the AKTX After Hours Price?
AKTX's last after hours stock price is 13.6600 USD, the stock has decreased by 0.2600, or 1.9400%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.